Incyte (INCY) and Syndax Pharmaceuticals (SNDX) said Wednesday that the US Food and Drug Administration has approved Niktimvo as a treatment for certain patients with chronic graft-versus-host disease who weigh at least 40 kg.
The company said the drug will be available in two vial sizes -- 9 mg and 22 mg -- and is expected to be available for order in the US starting in early February.
Health care providers can order Niktimvo through a network of specialty distributors.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。